Search
Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Mixtures: Mixed Salts of a Single-Entity Amphetamine Product, Mixed Salts of a Single-Entity Amphetamine ProductSynonyms: d-amphetamineNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTrioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnThe photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. … cross-linked specifically to a mutant mRNA sequence without affecting normal transcripts differing at even a single base pair.
Potassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigational[T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient. … Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution.
Mixtures: Isotonix Advanced B-complex Vitamins With Potassium and MagnesiumEpinephrine
go.drugbank.com/drugs/DB00668ApprovedInvestigationalVet approvedEpinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions.
Mixtures: D-Care 100X, Ultracaine DS InjElotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. … Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein.
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.
Categories: Endothelin A Receptor AntagonistsCalcium threonate
go.drugbank.com/drugs/DB11168ApprovedWithdrawnCalcium threonate is a calcium salt of threnoic acid and a novel drug developed for the treatment of osteoporosis and as a calcium supplement [A27266]. … L-threonate is an active metabolite of vitamin C that mediates a stimulatory action on vitamin C uptake [A27266].
Mixtures: OB Complete DHA, Iron Aspartate Glycinate and Polysaccharide Complex, Ascorbic Calcium, Vitamin B12, Folic Acid, Calcium Threonate and Succinic AcidApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIn a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].